ACR: Strontium ranelate cuts progression of knee OA

ACR: strontium ranelate cuts progression of knee OA
The osteoporosis therapeutic strontium ranelate reduces radiographic and radiological progression of knee osteoarthritis, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 10 to 14 in Washington, D.C.

(HealthDay)—The osteoporosis therapeutic strontium ranelate (SrRan) reduces radiographic and radiological progression of knee osteoarthritis, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 10 to 14 in Washington, D.C.

Jean-Yves Reginster, M.D., Ph.D., from the University of Liège in Belgium, and colleagues conduced a double-blind, placebo-controlled three-year study involving 1,371 patients (63 ± 7 years; 69 percent female) with symptomatic primary knee OA (Kellgren and Lawrence grade 2 or 3, joint space width [JSW] 3.5 ± 0.8 mm) who were randomized to receive SrRan (1 or 2 g/day) or placebo.

The researchers found that SrRan correlated with less progression of cartilage degradation and a significantly smaller decrease in JSW (−0.23 ± 0.56 mm with 1 g/day; −0.27 ± 0.63 mm with 2 g/day; and −0.37 ± 0.59 mm with placebo), with no difference between doses. SrRan at both doses also correlated with significantly less radiological and radioclinical progression. SrRan at the 2 g/day dose led to significant reductions in total Western Ontario and McMaster Universities Osteoarthritis Index score, including the pain and physical function subscores and . SrRan was well tolerated, with 17 percent of the patients in each group reporting a serious emergent adverse effect.

"Results of the present trial show also [SrRan's] ability to reduce the progression of osteoarthritis," Reginster said in a statement. "This could be a major step in the global management of musculo-skeletal disorders in the ."

Several authors disclosed to pharmaceutical companies, including Servier Laboratories, the manufacturer of strontium ranelate.

More information: Abstract
More Information

add to favorites email to friend print save as pdf

Related Stories

Study looks at pain processing abnormalities in knee OA

Sep 17, 2012

(HealthDay)—For patients with knee osteoarthritis (K-OA), the lack of correlation between clinical pain and radiographic evidence of disease severity may be due to central sensitization, according to a ...

Walking speed is a marker for knee osteoarthritis

Mar 20, 2012

(HealthDay) -- Slower walking speed may be a marker for identifying those at risk for knee osteoarthritis (OA), according to a study published online March 5 in Arthritis Care & Research.

Recommended for you

Osteoarthritis patients will benefit from jumping exercise

Feb 18, 2015

Progressive high-impact training improved the patellar cartilage quality of the postmenopausal women who may be at risk of osteoporosis (bone loss) as well as at risk of osteoarthritis. This was found out in the study carry ...

Use of nondrug, nonsurgical options low in hip, knee OA

Feb 16, 2015

(HealthDay)—Usage of nondrug, nonoperative interventions in community-dwelling individuals with hip and knee osteoarthritis (OA) is low, according to research published in the February issue of Arthritis Ca ...

Prevalence of fibromyalgia varies with criteria applied

Feb 13, 2015

(HealthDay)—The prevalence of fibromyalgia varies with the different sets of the American College of Rheumatology (ACR) classification criteria, according to a study published in the February issue of Arthritis & ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.